Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Lung Cancer Clinical Trials

A listing of Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (1565) clinical trials

A research study is analyzing blood samples to further the development of cancer screening technologies. This research study may be an option if you: Are at least 18 years of age Meet one of the following criteria: Have been diagnosed with stage IV colorectal cancer Have been diagnosed with IIIB ...

Phase N/A

People with Non-Small Cell Lung Cancer (NSCLC) are asked to participate in a research study being conducted by Montefiore Medical Center.

Phase N/A

Glesatinib is an orally administered multi-targeted tyrosine kinase inhibitor (TKI) that primarily targets the Axl and Mesenchymal-Epithelial Transition (MET) receptors. Sitravatinib is an orally-available, potent small molecule inhibitor or a closely related spectrum of receptor tyrosine kinases (RTKs) including MET, Axl, MERTK, VEGFR family, PDGFR family, KIT, FLT3, Trk family, ...

Phase

The purpose of this study is to evaluate the safety and tolerability of INCB039110 in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Phase N/A

Experimental tests, such as those used on the blood collected in this research study are also known as “investigational.” This means the tests have not been approved by the U.S. Food and Drug Administration (FDA). In this research study, the accuracy of these blood tests will be determined by comparing ...

Phase N/A

People with Non-Small Cell Lung Cancer are asked to participate in a research study being conducted by Montefiore Medical Center.

Phase N/A

Advanced tumors evade host immune responses by down regulation of major histocompatibility complex (MHC) molecules and tumor antigens and by creating an immune suppressive microenvironment around the tumor. Histone deacetylases (HDACs) have been implicated in the epigenetic regulation of innate and adaptive immunity. Increasing evidence supports the proposal that spectrum-selective ...

Phase N/A

The objective of this study is to describe the occurrence of AEs leading to dose reduction following afatinib treatment in NSCLC patients with common EGFR mutations (Deletion 19 and/or L858R) who are 70 years of age or older.

Phase

MGCD265 is an orally administered receptor tyrosine kinase inhibitor that targets MET and other receptors. This study is a Phase 2 trial of MGCD265 in patients with locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) that has activating genetic changes of the MET gene (mutation or amplification [increase ...

Phase

Characterize the safety, tolerability, ECG effects, pharmacokinetics and immunogenicity of anetumab ravtansine given as single agent and after inhibition of CYP3A4 and P-gp by concomitant administration of itraconazole in subjects with mesothelin-expressing advanced solid cancers

Phase